Yuuwa provides both capital and expertise to help scale our portfolio companies.

About us

Yuuwa Capital is a $40 million early stage venture capital firm based in Perth, Western Australia.

The fund was established in 2009 with investment from the Australian Federal Government's Innovation Investment Fund program and private investors. The fund's investment focus is biotechnology and software.

Yuuwa provides both capital and expertise to help founders, management and early investors scale our portfolio companies.

Yuuwa Capital's current fund is now fully allocated and no longer seeking new investment opportunities. We remain interested in seeing new projects where there may be synergies to our portfolio companies.

The Team


Matt Macfarlane


Matt is no longer active in the day-to-day operations of Yuuwa.

Matt has been both an investor and an entrepreneur in early stage ICT startups.  In his prior role he managed all aspects of the investment review, approval and closing process, and worked hands-on with Yuuwa’s portfolio companies to assist them in building teams, accelerating their growth, achieving milestones and securing additional financing.

Matt currently holds directorships with PetRescue, Spacecubed and AEGIC.  He is an active participant in the Perth start-up community through roles as advisor, director, judge, mentor and program lead for various early-stage programs.


Liddy McCall

LLB BJuris BCom(Hons) GAICD

Liddy has over 15 years as a founder, investor and management in early stage startups.   Her prior experience includes co-founder of iCeutica Inc group (acquired), Dimerix Limited (ASX listed) and Argus Biomedical Pty Ltd (acquired).  Before working with start-ups Liddy was an Associate Director, Macquarie Bank focusing on mergers and acquisitions.  She has been admitted as a barrister and solicitor in various Australian jurisdictions.  Liddy is involved in all aspects of investing, building and supporting Yuuwa’s portfolio companies.  Liddy is on the Board of various Yuuwa investee companies including ASX listed AdAlta Limited, Agworld Pty Ltd and Fitgenes Australia Limited.


James Williams

James is an accomplished scientist, entrepreneur and investor. He has been involved from concept to commercialisation, including CEO, CTO and Board roles, of numerous biotech companies which have resulted in five FDA approved drugs and devices. He conceived the technology behind iCeutica Inc (acquired in 2011) and co-discovered the lead therapy for ASX-listed Dimerix Limited (ASX:DXB), currently in Phase 2 trials for Chronic Kidney Disease.
James is involved in all phases of investment across the Yuuwa portfolio, and is currently a Director of Adalta Limited (ASX:1AD), PolyActiva Pty Ltd, iCetana Pty Ltd and Nexgen Plants Pty Ltd. He remains Chairman of Dimerix and is on the Board of Linear Clinical Research Ltd, a not-for-profit clinical trial facility.

Our Portfolio


© Yuuwa Capital All rights reserved | Site by OM4